Serum Lipoprotein-a as a Marker of Severity of Coronary Artery Disease in Aortic Valve Sclerosis Patients

Sohag University

Status: Completed

Conditions: Coronary Artery Disease; Lipoprotein(A); Serum; Aortic Valve Sclerosis; Severity

Treatments: Other: Serum Lipoprotein-a level

Study type: Observational

Funder types: Other

Identifiers

NCT07209631

Soh-Med-24-09-5PD

Details and patient eligibility

About

This work aimed to evaluate the association of serum level of Lp(a) with the severity of coronary artery disease (CAD) in aortic valve sclerosis (AVS) patients.

Full description

Aortic valve sclerosis (AVS) has a prevalence of 2% to 7% in the population above 65 years of age. In industrialized countries, aortic valve sclerosis is most frequently caused by progressive calcification and degeneration of the aortic cusps.

Coronary artery disease (CAD) is the most significant single cause of death in the world. In developed countries, more than 25% of all deaths in persons older than 35 years are due to CAD. More than half of acute myocardial infarctions occur without previous history or symptoms of CAD.

In recent years, there has been a special emphasis on lipoprotein(a) (Lp(a)), a significant, causal, and nonmodifiable predictor of valvular outcomes and CAD in the general population

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years.
• Both sexes.
• Patients with chest pain and/or dyspnea were diagnosed provisionally as having coronary artery disease.

Exclusion criteria

• Aortic stenosis.
• Aortic prosthesis.
• Untreated hypothyroidism.
• Severe chronic kidney failure.
• Administration of anti-inflammatory or immunosuppressive drugs.
• Pregnancy.

Trial design

100 participants in 1 patient group

Study group

Description:

Patients with chest pain and/or dyspnea were diagnosed provisionally as having coronary artery disease.

Treatment:

Other: Serum Lipoprotein-a level